Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Incidence and Survival Outcomes of Secondary Malignancies Among Survivors of Waldenström Macroglobulinemia

Jorge J. Castillo, MD, Adam J. Olszewski, MD, Sandra Kanan, NP, Kirsten Meid, MPH, Zachary Hunter, Steven P Treon, MD MA, PhD

Blood (2014) 124 (21): 855.

https://doi.org/10.1182/blood.V124.21.855.855

Published: 2014

Journal Articles

Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia

Irene M. Ghobrial, MD, Robert Allyn Redd, MS, Jeffrey Matous, Philippe Armand, MD PhD, Erica N Boswell, BS, Stacey Chuma, BSN, Kimberly Noonan, RN, NP, AOCN, Megan H. MacNabb, BA, Ranjit Banwait, Courtney Hanlon, Houry Leblebjian, PharmD, BCOP, Diane Warren, Jorge J. Castillo, MD, Jacob P. Laubach, MD, Claudia E. Paba-Prada, MD, Kenneth C. Anderson, MD, Paul G. Richardson, Edie A. Weller, PhD, Steven P Treon, MD MA, PhD

Blood (2014) 124 (21): 3081.

https://doi.org/10.1182/blood.V124.21.3081.3081

Published: 2014

Journal Articles

Clinical Characteristics of Rituximab Intolerance in Patients with Waldenstrom's Macroglobulinemia

Sandra Kanan, NP, Kirsten Meid, MPH, Steven P Treon, MD MA, PhD, Jorge J. Castillo, MD

Blood (2014) 124 (21): 2610.

https://doi.org/10.1182/blood.V124.21.2610.2610

Published: 2014

Journal Articles

Thalidomide in Combination with Rituximab Is Active in Waldenström’s Macroglobulinemia and May Overcome Poor Response Determinants Associated with Rituximab Monotherapy.

Steven P. Treon, MD, MA, PhD, Zachary Hunter, BS, Christopher J. Patterson, BS, Andrew R. Branagan, BS

Blood (2005) 106 (11): 2442.

https://doi.org/10.1182/blood.V106.11.2442.2442

Published: 2005

Journal Articles

Phase II Study of CC-5013 (Revlimid) and Rituximab in Waldenström’s Macroglobulinemia: Preliminary Safety and Efficacy Results.

Steven P. Treon, MD, MA, PhD, Christopher J. Patterson, BS, Zachary R. Hunter, BS, Andrew R. Branagan, BS

Blood (2005) 106 (11): 2443.

https://doi.org/10.1182/blood.V106.11.2443.2443

Published: 2005

NARROW

Incidence and Survival Outcomes of Secondary Malignancies Among Survivors of Waldenström Macroglobulinemia

Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia

Clinical Characteristics of Rituximab Intolerance in Patients with Waldenstrom's Macroglobulinemia

Thalidomide in Combination with Rituximab Is Active in Waldenström’s Macroglobulinemia and May Overcome Poor Response Determinants Associated with Rituximab Monotherapy.

Phase II Study of CC-5013 (Revlimid) and Rituximab in Waldenström’s Macroglobulinemia: Preliminary Safety and Efficacy Results.

Email alerts

ASH Publications

American Society of Hematology

Incidence and Survival Outcomes of Secondary Malignancies Among Survivors of Waldenström Macroglobulinemia

Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia

Clinical Characteristics of Rituximab Intolerance in Patients with Waldenstrom's Macroglobulinemia

Thalidomide in Combination with Rituximab Is Active in Waldenström’s Macroglobulinemia and May Overcome Poor Response Determinants Associated with Rituximab Monotherapy.

Phase II Study of CC-5013 (Revlimid) and Rituximab in Waldenström’s Macroglobulinemia: Preliminary Safety and Efficacy Results.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only